5.15
0.01 (0.19%)
| Previous Close | 5.14 |
| Open | 5.10 |
| Volume | 561,755 |
| Avg. Volume (3M) | 311,440 |
| Market Cap | 224,506,528 |
| Price / Sales | 37.76 |
| Price / Book | 5.91 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2025 - 19 May 2025 |
| Diluted EPS (TTM) | -1.55 |
| Total Debt/Equity (MRQ) | 52.35% |
| Current Ratio (MRQ) | 6.08 |
| Operating Cash Flow (TTM) | -56.02 M |
| Levered Free Cash Flow (TTM) | -37.88 M |
| Return on Assets (TTM) | -46.41% |
| Return on Equity (TTM) | -216.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Abeona Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.75 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.59% |
| % Held by Institutions | 68.18% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 288.35%) | Buy |
| Median | 18.00 (249.52%) | |
| Low | 16.00 (Oppenheimer, 210.68%) | Buy |
| Average | 18.00 (249.52%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Apr 2025 | 20.00 (288.35%) | Buy | 5.33 |
| 24 Mar 2025 | 15.00 (191.26%) | Buy | 5.12 | |
| Oppenheimer | 05 Mar 2025 | 16.00 (210.68%) | Buy | 5.26 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |